Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after the market closes. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update.

Investors and interested parties can join the call using the provided domestic (1-800-267-6316) or international (1-203-518-9783) dial-in numbers, with the conference ID: CRNXQ2. Alternatively, participants can access the call via a live webcast on the Events section of the Crinetics website. It is recommended to join at least 15 minutes before the scheduled start time. The webcast will be archived on the company's Investor Relations section for future reference.

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, August 8^th @ 4:30 PM ET

Domestic:	1-800-267-6316
International:	1-203-518-9783
Conference ID:	CRNXQ2

Participants can use the dial-in numbers above OR access the call via live webcast on the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to scheduled start of the call.

The webcast will be archived on the Investor Relations sections of www.crinetics.com.

About Crinetics Pharmaceuticals 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.

Contact:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

Source: Crinetics Pharmaceuticals, Inc.

FAQ

When will Crinetics Pharmaceuticals (CRNX) report its Q2 2024 financial results?

Crinetics Pharmaceuticals (CRNX) will report its second quarter 2024 financial results on Thursday, August 8, 2024, after the market closes.

What time is the Crinetics Pharmaceuticals (CRNX) Q2 2024 earnings call scheduled for?

The Crinetics Pharmaceuticals (CRNX) Q2 2024 earnings call is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET.

How can investors access Crinetics Pharmaceuticals' (CRNX) Q2 2024 earnings call?

Investors can access Crinetics Pharmaceuticals' (CRNX) Q2 2024 earnings call by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with the conference ID: CRNXQ2, or via a live webcast on the Events section of the Crinetics website.

Where can I find the archived webcast of Crinetics Pharmaceuticals' (CRNX) Q2 2024 earnings call?

The archived webcast of Crinetics Pharmaceuticals' (CRNX) Q2 2024 earnings call will be available on the Investor Relations section of www.crinetics.com.